Translarna™ (ataluren)* has been approved in the European Union for ambulatory patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.

Translarna Summary of Product Characteristics

Learn more at www.translarna.co.uk

*Translarna is an investigational new drug in the US

 

 

EMFLAZA® (deflazacort) is approved in the US for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older.

Please see the accompanying full Prescribing Information

Click here for Important Safety Information

Learn more at www.emflaza.com

For medical information, product complaints, or to report an adverse event, please call 1‑866‑562‑4620.

You may report adverse events to FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch

 

TEGSEDI™ (inotersen): has received marketing authorisation approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). PTC will commercialize TEGSEDI™ (inotersen) in Latin America (LATAM).

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue